エゼチミブとフィトステロールの組み合わせによるコレステロール代謝への作用:ヒトにおけるランダム化,制御された給餌試験
Xiaobo Lin1, Susan B Racette, Michael Lefevre
1Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Circulation
|July 20, 2011
まとめ
エゼチミブにフィトステロールを添加すると,コレステロールの代謝が大幅に改善され,LDLコレステロールが低下します. この組み合わせ治療は,高コレステロール血症の管理に有望であることが示されています.
科学分野:
- 心血管研究 循環器科の研究
- 栄養科学とは,栄養科学である.
- 薬理学 薬理学とは
背景:
- エゼチミブとフィトステロールは,コレステロールの吸収を抑制することが知られている.
- この研究では,エゼチミブとフィトステロールを組み合わせることで生じる相乗効果を調査した.
研究 の 目的:
- エゼチミブとフィトステロールを併用したエゼチミブがコレステロール代謝を変化させるのに,エゼチミブ単独より効果的であるという仮説を検証する.
- 腸内コレステロール吸収,糞便コレステロール排泄,およびLDLコレステロールレベルへの影響を評価するために.
主な方法:
- ランダム化,ダブルブラインド,プラセボ対照,トリプルクロスオーバー研究で,21人の軽度の高コレステロールの被験者を対象とした.
- 被験者は,それぞれ3週間,エゼチミブプラセボ+フィトステロールプラセボ,エゼチミブ+フィトステロールプラセボ,またはエゼチミブ+フィトステロールをコントロールされた食事で摂取しました.
- すべての食事は代謝キッチンで提供され,食事のコントロールが確保されました.
主要な成果:
- エゼチミブとフィトステロールの併用は,対照群とエゼチミブ単独と比較して,腸内コレステロール吸収を著しく低下させた (P<0.0001).
- 中のコレステロールの分泌は,併用治療で有意に増加した (P<0.0001).
- 低密度の脂質タンパク質コレステロールの血レベルは,対照群と比較して,エゼチミブ+フィトステロールで有意に低下した (101 mg/dL vs. 129 mg/dL; P<0.0001).
結論:
- エゼチミブにフィトステロールを添加することで,コレステロール代謝とLDLコレステロールの減少に対する効果が著しく強化されました.
- ダイエットと薬理学的介入の組み合わせは,高コレステロール血症の補助療法としてのフィトステロールの可能性を強調しています.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Lipids: Dietary Sources and Requirements
2.5K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.5K
Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
400
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
400
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


